{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:34:19Z","timestamp":1791318859192,"version":"4.3.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jaad.2013.12.037","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T09:44:54Z","timestamp":1399974294000},"page":"979.e1-979.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Topical pharmacotherapy for skin cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Giuseppe","family":"Micali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lacarrubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Nasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.12.037_bib1","first-page":"20","article-title":"An update on nonmelanoma skin cancer","volume":"4","author":"Patel","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjoto.2008.03.002","article-title":"Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behaviour","volume":"30","author":"McGuire","year":"2009","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.jaad.2013.12.037_bib3","unstructured":"Centre for Evidence Based Medicine web site. OCEBM Levels of Evidence System. Available at: http:\/\/www.cebm.net\/index.aspx?o=5653. Accessed February 22, 2014."},{"key":"10.1016\/j.jaad.2013.12.037_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracil treatment for actinic keratosis\u2014a systematic review of randomized controlled trials","volume":"48","author":"Askew","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/978-0-387-78574-5_36","article-title":"Topical treatment of field cancerization","volume":"146","author":"Ulrich","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2013.12.037_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.2007.08268.x","article-title":"Management of field change in actinic keratosis","volume":"157","author":"Vatve","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib7","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: a comprehensive strategy","volume":"11","author":"Stockfleth","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"1 Suppl 1","key":"10.1016\/j.jaad.2013.12.037_bib8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2012.09.051","article-title":"Current issues in the management of actinic keratosis","volume":"68","author":"Ceilley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib9","first-page":"81","article-title":"Tumors of the skin: effects of local use of cytostatic agents","volume":"1","author":"Klein","year":"1962","journal-title":"Skin (Los Angeles)"},{"key":"10.1016\/j.jaad.2013.12.037_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.2930030314","article-title":"Tumors of the skin. XII. Topical 5-Fluorouracil for epidermal neoplasms","volume":"3","author":"Klein","year":"1971","journal-title":"J Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2013.12.037_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000252591","article-title":"The effects of 5-fluorouracil (5-FU) ointment in the treatment of neoplastic dermatoses","volume":"140","author":"Klein","year":"1970","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2013.12.037_bib12","series-title":"Clinical immunotherapy","first-page":"31","article-title":"Accessible tumors","author":"Klein","year":"1980"},{"key":"10.1016\/j.jaad.2013.12.037_bib13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.sder.2004.06.005","article-title":"Topical treatment strategies for non-melanoma skin cancer and precursor lesions","volume":"23","author":"McGillis","year":"2004","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/157488706775246166","article-title":"Topical therapy for actinic keratoses: current and evolving therapies","volume":"1","author":"Weinberg","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.jaad.2013.12.037_bib15","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/14656566.2010.481284","article-title":"Treating skin cancer with topical cream","volume":"11","author":"Micali","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2013.12.037_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1684\/ejd.2013.1923","article-title":"Therapeutic strategies for actinic keratoses\u2014a systematic review","volume":"23","author":"Nashan","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"de Berker","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09546630903341937","article-title":"Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment","volume":"21","author":"Kaur","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2013.12.037_bib19","first-page":"20","article-title":"Nonsurgical innovations in the treatment of nonmelanoma skin cancer","volume":"3","author":"Amini","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.jid.5700264","article-title":"Imiquimod for actinic keratoses: systematic review and meta-analysis","volume":"126","author":"Hadley","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaad.2006.05.030","article-title":"Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials","volume":"55","author":"Falagas","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-a","article-title":"Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study","volume":"140","author":"Stockfleth","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00403-005-0601-9","article-title":"Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies","volume":"297","author":"Pirard","year":"2005","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2013.12.037_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","article-title":"Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group","volume":"26","author":"Pflugfelder","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.12.037_bib28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.12.037_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","article-title":"Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses","volume":"149","author":"Lebwohl","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1 Suppl 1","key":"10.1016\/j.jaad.2013.12.037_bib30","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jaad.2012.09.050","article-title":"Clinical findings using ingenol mebutate gel to treat actinic keratoses","volume":"68","author":"Martin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib31","series-title":"Retinoids in cutaneous malignancy","first-page":"66","article-title":"Topical therapy of actinic keratoses with tretinoin","author":"Kligman","year":"1991"},{"key":"10.1016\/j.jaad.2013.12.037_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0190-9622(94)70054-0","article-title":"Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses","volume":"30","author":"Alirezai","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/mjd.2003.451","article-title":"Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial","volume":"49","author":"Kang","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2008.08615.x","article-title":"A phase II dose-ranging study of topical resiquimod to treat actinic keratosis","volume":"159","author":"Szeimies","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/11311170-000000000-00000","article-title":"Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score","volume":"11","author":"Campione","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/2047-783X-16-2-67","article-title":"Topical treatment of actinic keratoses with potassium dobesilate 5% cream. a preliminary open-label study","volume":"16","author":"Cuevas S\u00e1nchez","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jaad.2013.12.037_bib37","first-page":"128","article-title":"Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study","volume":"7","author":"Huyke","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2013.12.037_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/120347540500900501","article-title":"Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies","volume":"9","author":"Gupta","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/09546630701818870","article-title":"Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis","volume":"19","author":"Kose","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2013.12.037_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2230.2010.03999.x","article-title":"Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses","volume":"36","author":"Akarsu","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results","volume":"165","author":"Stockfleth","year":"2011","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2013.12.037_bib42","first-page":"CD004415","article-title":"Interventions for actinic keratoses","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2013.12.037_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaad.2012.06.009","volume":"67","author":"Connolly","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-4632.2010.04826.x","article-title":"Basal cell carcinoma: evidence-based medicine and review of treatment modalities","volume":"50","author":"Kwasniak","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/jid.1965.62","article-title":"Tumors of the skin. IV. Double-blind study on effects of local administration of anti-tumor agents in basal cell carcinoma","volume":"44","author":"Klein","year":"1965","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1524-4725.2000.99227.x","article-title":"A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier","volume":"26","author":"Romagosa","year":"2000","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib47","first-page":"433","article-title":"5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction","volume":"33","author":"Gross","year":"2007","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib48","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/archderm.1982.01650230056029","article-title":"Nodular superficial pigmented basal cell epitheliomas. Long-term fluorouracil treatment","volume":"118","author":"Shelley","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib49","first-page":"191","article-title":"Multiple basal cell carcinomas of lower legs with stasis dermatitis: a therapeutic challenge","volume":"20","author":"\u010ceovi\u0107","year":"2012","journal-title":"Acta Dermatovenerol Croat"},{"key":"10.1016\/j.jaad.2013.12.037_bib50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2133.2012.11061.x","article-title":"Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials","volume":"167","author":"Roozeboom","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib51","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized vehicle-controlled study","volume":"47","author":"Geisse","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib52","first-page":"677","article-title":"Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe","volume":"18","author":"Gollnick","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib53","first-page":"318","article-title":"Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study","volume":"85","author":"Quirk","year":"2010","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.12.037_bib54","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archderm.138.9.1165","article-title":"Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens","volume":"138","author":"Shumack","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/09546634.2010.548503","article-title":"Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review","volume":"22","author":"Lacarrubba","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2013.12.037_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/09546630260199488","article-title":"Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report","volume":"13","author":"Micali","year":"2002","journal-title":"J Dermatolog Treat"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2013.12.037_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2230.28.s1.7.x","article-title":"The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin\u2019s syndrome","volume":"28","author":"Micali","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib58","first-page":"1","article-title":"Ingenol mebutate: an introduction","volume":"17","author":"Fallen","year":"2012","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaad.2013.12.037_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-0960.2010.00626.x","article-title":"PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial","volume":"51","author":"Siller","year":"2010","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib60","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199912023412312","article-title":"Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma","volume":"341","author":"Peris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.12.037_bib61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jaad.2005.04.014","article-title":"Treatment of basal cell carcinoma with dobesilate","volume":"53","author":"Cuevas","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib62","article-title":"Treatment of infiltrative basal cell carcinomas by inhibiting the fibroblast growth factor (FGF)-signal transducer and activator of transcription (STAT)-3 signalling pathways","author":"Cuevas","year":"2011","journal-title":"J Cancer Sci Ther"},{"key":"10.1016\/j.jaad.2013.12.037_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1470-2045(13)70143-8","article-title":"Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial","volume":"14","author":"Arits","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2013.12.037_bib64","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaad.2007.05.022","article-title":"A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma","volume":"57","author":"Eigentler","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib65","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1365-4632.2010.04581.x","article-title":"Use of dermatoscopy and videodermatoscopy in therapeutic follow up: a review","volume":"49","author":"Lacarrubba","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib66","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0030-4220(81)90362-5","article-title":"Evaluation of 5-fluorouracil in the treatment of actinic keratosis of the lip","volume":"52","author":"Warnock","year":"1981","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.jaad.2013.12.037_bib67","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archotol.1989.01860310086029","article-title":"Actinic cheilitis. A prospective study comparing four treatment methods","volume":"115","author":"Robinson","year":"1989","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2013.12.037_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2133.2007.07863.x","article-title":"Management of actinic cheilitis using diclofenac 3% gel: a report of six cases","volume":"156","author":"Ulrich","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2011.09.039","article-title":"Solar cheilosis: an ominous precursor part II. Therapeutic perspectives","volume":"66","author":"Jadotte","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2004.00025.x","article-title":"Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment","volume":"45","author":"Arlette","year":"2004","journal-title":"Austral J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/120347540300700201","article-title":"Topical treatment of Bowen\u2019s disease with 5-fluorouracil","volume":"7","author":"Bargman","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2133.2003.05033.x","article-title":"Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen\u2019s disease","volume":"148","author":"Salim","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib73","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2006.01.055","article-title":"Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen\u2019s disease): a randomized, double blind, placebo-controlled trial","volume":"54","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/TCRM.S1109","article-title":"Advances in the use of topical imiquimod to treat dermatologic disorders","volume":"4","author":"Lacarrubba","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jaad.2013.12.037_bib75","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2230.2005.01867.x","article-title":"Two cases of Bowen\u2019s disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel","volume":"30","author":"Dawe","year":"2005","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2013.12.037_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2133.2007.07859.x","article-title":"Does progression from actinic keratosis and Bowen\u2019s disease end with treatment: diclofenac 3% gel, an old drug in a new environment?","volume":"156","author":"Patel","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib77","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.05.007","article-title":"Penile cancer","volume":"54","author":"Micali","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5021\/ad.2009.21.4.419","article-title":"A case of erythroplasia of Queyrat treated with imiquimod 5% cream and excision","volume":"21","author":"Choi","year":"2009","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib79","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/1097-0142(197610)38:4<1498::AID-CNCR2820380409>3.0.CO;2-#","article-title":"Erythroplasia of Queyrat: treatment with topical 5-fluorouracil","volume":"38","author":"Goette","year":"1976","journal-title":"Cancer"},{"issue":"4 Suppl","key":"10.1016\/j.jaad.2013.12.037_bib80","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1067\/mjd.2002.126580","article-title":"Treatment of squamous cell\u00a0carcinoma in situ of the penis with 5% imiquimod cream:\u00a0a case report","volume":"47","author":"Orengo","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib81","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1067\/mjd.2002.120444","article-title":"Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream","volume":"46","author":"Schroeder","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib82","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2006.07.021","article-title":"Erythroplasia of Queyrat treated with imiquimod 5% cream","volume":"55","author":"Micali","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib83","first-page":"4","article-title":"Extramammary Paget disease","volume":"17","author":"Hartman","year":"2011","journal-title":"Dermatol Online J"},{"issue":"Suppl 4","key":"10.1016\/j.jaad.2013.12.037_bib84","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1067\/mjd.2002.126584","article-title":"Treatment of primary limited cutaneous extramammary Paget\u2019s disease with topical imiquimod monotherapy: two case reports","volume":"47","author":"Zampogna","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib85","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.lpm.2011.04.005","article-title":"Successful treatment of recurrent extramammary Paget's disease of the penis and scrotum with imiquimod 5% cream","volume":"40","author":"Gil-Bistes","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.jaad.2013.12.037_bib86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3315\/jdcr.2011.1073","article-title":"Treatment of vulvar Paget disease with topical imiquimod: a case report and review of the literature","volume":"5","author":"Feldmeyer","year":"2011","journal-title":"J Dermatol Case Rep"},{"key":"10.1016\/j.jaad.2013.12.037_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/LGT.0b013e31822d2484","article-title":"Conservative management of extramammary Paget disease with imiquimod","volume":"16","author":"Baiocchi","year":"2012","journal-title":"Low Genit Tract Dis"},{"key":"10.1016\/j.jaad.2013.12.037_bib88","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaad.2010.04.035","article-title":"Extramammary Paget disease: failure to respond to topical imiquimod 5%","volume":"65","author":"Jim On","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1529-8019.2012.01428.x","article-title":"Sequential use with imiquimod and surgery in extramammary Paget\u2019s disease","volume":"25","author":"Toledo","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2013.12.037_bib90","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2133.1994.tb08535.x","article-title":"Extramammary Paget\u2019s disease of the scrotum: treatment with topical 5-fluorouracil and plastic surgery","volume":"131","author":"Bewley","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib91","first-page":"331","article-title":"Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil","volume":"65","author":"Del Castillo","year":"2000","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.12.037_bib92","first-page":"245","article-title":"Extramammary Paget\u2019s disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid: a case report","volume":"77","author":"Ye","year":"2006","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.12.037_bib93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cps.2009.08.006","article-title":"Lentigo maligna: diagnosis and treatment","volume":"37","author":"Bosbous","year":"2010","journal-title":"Clin Plast Surg"},{"issue":"Suppl 66","key":"10.1016\/j.jaad.2013.12.037_bib94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.0366-077X.2003.05637.x","article-title":"Treatment of lentigo maligna with topical imiquimod","volume":"149","author":"Naylor","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib95","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2133.2006.07476.x","article-title":"Imiquimod in the treatment of lentigo maligna","volume":"155","author":"Rajpar","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib96","first-page":"1077","article-title":"Videodermatoscopy of lentigo maligna treated with imiquimod","volume":"7","author":"Micali","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archderm.144.7.943","article-title":"Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients","volume":"144","author":"Buettiker","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib98","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00042728-200802000-00002","article-title":"Treatment of lentigo maligna with imiquimod before staged excision","volume":"34","author":"Cotter","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib99","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1365-2133.2009.09032.x","article-title":"Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up","volume":"160","author":"Powell","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib100","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaad.2009.08.023","article-title":"Imiquimod use in the treatment of lentigo maligna","volume":"61","author":"Junkins-Hopkins","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib101","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ad.2011.03.003","article-title":"Imiquimod in the treatment of lentigo maligna","volume":"102","author":"Nagore","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaad.2013.12.037_bib102","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archdermatol.2011.260","article-title":"Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients","volume":"147","author":"Ly","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib103","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-4632.2010.04423.x","article-title":"Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery","volume":"49","author":"Erickson","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2003.07.005","article-title":"Treatment of lentigo maligna with tazarotene 0.1% gel","volume":"50","author":"Chimenti","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib105","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.1524-4725.2009.01227.x","article-title":"Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod","volume":"35","author":"Woodmansee","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2013.12.037_bib106","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archderm.139.7.945","article-title":"Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease","volume":"139","author":"Fisher","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib107","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/archdermatol.2010.237","article-title":"Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production","volume":"146","author":"Martires","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib108","first-page":"555","article-title":"Topical imiquimod treatment of a cutaneous melanoma metastasis","volume":"43","author":"Steinmann","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.12.037_bib109","first-page":"534","article-title":"Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy","volume":"7","author":"Heber","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2013.12.037_bib110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0560.2009.01290.x","article-title":"Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis","volume":"37","author":"Turza","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2013.12.037_bib111","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2013.12.037_bib112","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/dsu.12300","article-title":"Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons","volume":"39","author":"Chitwood","year":"2013","journal-title":"Dermatol Surg"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214010020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214010020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:52Z","timestamp":1759271452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214010020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0190962214010020"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.12.037","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical pharmacotherapy for skin cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}